The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study

Atherosclerosis

Volumn 139, Issue 1, 1998, Pages 49-56

  Humphries, Steve E ^a   Luong, Le Anh ^a   Talmud, Philippa J ^a   Frick, M Heikki ^b   Antero Kesaniemi Y ^c   Pasternack, Amos ^d   Taskinen, Marja Riitta ^b   Syvänne, Mikko ^b  

^a Department of Clinical Pharmacology   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Gemfibrozil; LOCAT; Stromelysin (MMP 3)

Indexed keywords

ANTILIPEMIC AGENT; DNA; GEMFIBROZIL; PLACEBO; STROMELYSIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR;

AGED; ANTILIPEMIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GEMFIBROZIL; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROMOTER REGIONS (GENETICS);

EID: 0032127219     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00053-7     Document Type: Article

References (25)

1. Newby A.C., Southgate K.M., Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol. 89:1994;59.
2. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Circulation. 91:1995;2125.
3. Nikkari S.T., O'Brien K.D., Ferguson M., Hatsukami T., Welgus H.G., Alpers C.E., Clowes A.W. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1995;1393.
4. Henney A.M., Wakeley P., Davies M.J., Foster K., Hembry R., Murphy G., Humphries S.E. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 88:1991;8154.
5. Murphy G, Reynolds JJ. Extracellular matrix degradation. In Connective Tissue and Its Heritable Disorders. New York: Wiley-Liss, 1993:287.
6. Quinones S., Buttice G., Kurkinen M. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem J. 302:1994;471.
7. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci. 748:1995;501.
8. Diaz-Meco M.T., Quinones S., Municio M.M., Sanz L., Bernal D., Cabrero E., Saus J., Moscat J. Protein kinase C-independent expression of stromelysin by platelet-derived growth factor, ras oncogene, and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem. 266:1991;22597.
9. Ye S., Watts G.F., Mandalia S., Humphries S.E., Henney A.M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 73:1995;209.
10. Ye S., Eriksson P., Hamsten A., Kirkinen M., Humphries S.E., Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 271:1996;13055.
11. Watts G.F., Lewis B., Brunt J.N.H., Lewis E.S., Coltart D.J., Smith L.D.R., Mann J.I., Swan A.V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' atherosclerosis regression study (STARS). Lancet. 339:1992;563.
12. Jukema J.W., Bruschke A.V.G., van Brown A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., Van-Rappard F.M., Lie K.I. Effects of lipid lowering pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS). Circulation. 91:1995;2528.
13. de Maat M.P.M., Jukema W., Ye S., Zwinderman A.H., Beekman M., Kastelein J.J.P., van Boven A.J., Bruschke A.V.G., Humphries S.E., Kluft C., Henney A.M. Efficacy of pravastatin treatment in coronary atherosclerosis is modulated by natural variation in the stromelysin- 1 promoter. Atherosclerosis. 130:1997;34.
14. Syvanne M., Taskinen M.-R., Nieminen M.S., Manninen V., Kesaniemi Y.A., Pasternack A., Nawrocki J.W., Haber H., Frick M.H. A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT study. Control Clin Trials. 18:1997;93.
15. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of high density lipoprotein cholesterol (for the Lopid Coronary Angiography Trial (LOCAT) study group). Circulation. 96:1997;2137-2143.
16. Schonbeck U., Mach F., Sukhova G.K., Murphy C., Bonnefoy J.Y., Fabunmi R.P., Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signalling in plaque rupture? Circ Res. 81:1997;448-454.
17. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin and tissue factor. Circulation. 96:1997;396-399.
18. Carty C.S., Soloway P.D., Kayastha S., Bauer J., Marsan B., Ricotta J.J., Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg. 24:1996;27-934.
19. Dawson S.J., Wiman B., Hamsten A., Green F., Humphries S., Henney A. The two allele sequences of a common polymorphisms in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in HepG2 cells. J Biol Chem. 268:1993;10739.
20. Eriksson P., Kallin B., Van't Hooft F.M., Bavenholm P., Hamsten A. Allele specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 92:1995;185.
21. Panahloo A., Mohamed-Ali V., Lane A., Green F., Humphries S.E., Yudkin J.S. Determinants of plasminogen activator inhibitor 1 activity in treated NIDMM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 44:1995;37.
22. Ossei-Gerning N., Mansfield M.W., Stickland M.H., Wilson I.J., Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vasc Biol. 17:1997;33.
23. Tybjaerg-Hansen A., Agerholm-Larsen B., Humphries S.E., Abildgaard S., Schnohr P., Nordestgaard B.G. A common mutation (G-455-A) in the beta-fibrinogen is an independent predictor of plasma fibrinogen, a risk factor for ischemic heart disease. J Clin Invest. 99:1997;3034-3039.
24. Humphries S.E., Thomas A., Montgomery H.E., Green F., Winder A., Miller G. Gene-environment interaction in the determination of plasma levels of fibrinongen. Fibrinol Proteol. 11(1):1997;3.
25. Smedley O. Do plaques grow upstream or downstream? An angiographic study in the femoral artery. Arteriocler Thromb Vasc Biol. 17:1997;912.